PMID- 3903508
OWN - NLM
STAT- MEDLINE
DCOM- 19851219
LR  - 20210103
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 313
IP  - 23
DP  - 1985 Dec 5
TI  - Observations on the systemic administration of autologous lymphokine-activated 
      killer cells and recombinant interleukin-2 to patients with metastatic cancer.
PG  - 1485-92
AB  - We describe here the preliminary results of the systemic administration of 
      autologous lymphokine-activated killer (LAK) cells and the recombinant-derived 
      lymphokine interleukin-2 to patients with advanced cancer. This regimen was based 
      on animal models in which the systemic administration of LAK cells plus 
      interleukin-2 mediated the regression of established pulmonary and hepatic 
      metastases from a variety of murine tumors in several strains of mice. We treated 
      25 patients with metastatic cancer in whom standard therapy had failed. Patients 
      received both 1.8 to 18.4 X 10(10) autologous LAK cells, generated from 
      lymphocytes obtained through multiple leukaphereses, and up to 90 doses of 
      interleukin-2. Objective regression of cancer (more than 50 per cent of volume) 
      was observed in 11 of the 25 patients: complete tumor regression occurred in one 
      patient with metastatic melanoma and has been sustained for up to 10 months after 
      therapy, and partial responses occurred in nine patients with pulmonary or 
      hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one 
      patient with a primary unresectable lung adenocarcinoma. Severe fluid retention 
      was the major side effect of therapy, although all side effects resolved after 
      interleukin-2 administration was stopped. Further development of this approach 
      and additional patient follow-up are required before conclusions about its 
      therapeutic value can be drawn.
FAU - Rosenberg, S A
AU  - Rosenberg SA
FAU - Lotze, M T
AU  - Lotze MT
FAU - Muul, L M
AU  - Muul LM
FAU - Leitman, S
AU  - Leitman S
FAU - Chang, A E
AU  - Chang AE
FAU - Ettinghausen, S E
AU  - Ettinghausen SE
FAU - Matory, Y L
AU  - Matory YL
FAU - Skibber, J M
AU  - Skibber JM
FAU - Shiloni, E
AU  - Shiloni E
FAU - Vetto, J T
AU  - Vetto JT
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Adult
MH  - Carcinoma, Renal Cell/therapy
MH  - Clinical Trials as Topic
MH  - Colonic Neoplasms/therapy
MH  - Humans
MH  - Immunization, Passive/adverse effects/*methods
MH  - Interleukin-2/administration & dosage/*immunology
MH  - Kidney Neoplasms/therapy
MH  - Killer Cells, Natural/immunology/*transplantation
MH  - Leukapheresis
MH  - Liver Neoplasms/secondary/therapy
MH  - Lung Neoplasms/secondary/therapy
MH  - Melanoma/therapy
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasms/immunology/*therapy
MH  - Recombinant Proteins/administration & dosage/immunology
MH  - Rectal Neoplasms/therapy
MH  - Transplantation, Autologous
EDAT- 1985/12/05 00:00
MHDA- 1985/12/05 00:01
CRDT- 1985/12/05 00:00
PHST- 1985/12/05 00:00 [pubmed]
PHST- 1985/12/05 00:01 [medline]
PHST- 1985/12/05 00:00 [entrez]
AID - 10.1056/NEJM198512053132327 [doi]
PST - ppublish
SO  - N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327.